Life sciences dealmaking came back in 2025, and artificial intelligence is poised to drive even more M&A activity in 2026 as companies move from hyping the technology to proving its value in drug ...

Life sciences leaders say AI agents will be "essential" within two years. 97% say trusted data is essential for effective use of AI agents. 81% of R&D leaders surveyed are "very excited" about using ...

Forbes contributors publish independent expert analyses and insights. William A. Haseltine, Ph.D., covers genomics and regenerative medicine Agentic AI sets research agendas, identifies connections in ...

Exclusive partnership brings to the U.S. personalized AI preventive care platform, validated in clinical trials by the UK's NHS, to save employers billions of dollars and improve millions of lives ...